Mirion Technologies (MION), a California-based provider of radiation detection, measurement, analysis and monitoring products and services to the nuclear, defense and medical end markets, is expected to price its IPO this week.
Business Overview (from prospectus)
We are a global provider of radiation detection, measurement, analysis and monitoring products and services to the nuclear, defense and medical end markets. Our customers rely on our solutions to protect people, property and the environment from nuclear and radiological hazards. Our products and services include: dosimeters; contamination & clearance monitors; detection & identification instruments; radiation monitoring systems; electrical penetrations; reactor instrumentation & control equipment and systems; dosimetry services; imaging systems; and related accessories, software and services. Many of our end markets are characterized by the need to meet rigorous regulatory standards, design qualifications and operating requirements. We believe these industry dynamics create substantial barriers to entry, thereby reinforcing our market position. We have leveraged the strength of our nuclear platform to expand the commercial applications of our technologies to defense and medical end markets.
Offering: 11 million shares at $15 - $17 per share. Net proceeds of approximately $96 million from the proceeds of issue of 7.8 million shares by the company (remaining shares offered by stockholders, the proceeds of which will not be received by the company) will be used for debt repayment and $8 million as payment to ACFS to terminate investment banking service agreement.
Consolidated revenue for the nine months ended March 31, 2010 was $166.0 million, an increase of $24.3 million from revenue of $141.7 million for the nine months ended March 31, 2009...Gross margin decreased 3.3% to 43.1% for the nine months ended March 31, 2010...Research and development expenses for the nine months ended March 31, 2010 were $6.0 million as compared to $9.1 million for the nine months ended March 31, 2009...Net income for the nine months ended March 31, 2010 were $295 thousand as compared to a loss of $9.8 million for the nine months ended March 31, 2009...
The global markets for our products and services are competitive and continually evolving. Within each of our operating segments, we encounter a variety of competitors, ranging from small independent companies providing niche solutions to larger multi-national corporations providing a broader set of products and services to our targeted end markets. We believe the primary competitors in each of our segments are Health Physics: Thermo Fisher Scientific (NYSE:TMO) and Areva; Radiation Monitoring Systems: General Atomics (Sorrento Electronics) and Areva (Canberra); Sensing Systems: Reuter-Stokes (General Electric) (NYSE:GE), Schott and Areva and Dosimetry Services: Landauer (NYSE:LDR).